Short-term outcomes (less than 1 month):
the rate of mortality was 0.001 (range: 0.00 - 0.01) for angiography, 0.01 (range: 0.00 - 0.03) for coronary stent placement, 0.01 (range: 0.00 - 0.03) for percutaneous transluminal coronary angioplasty (PTCA), and 0.04 (range: 0.01 - 0.06) for CABG;
the rate of minor complications was 0.04 (range: 0.01 - 0.07);
the rate of stroke was 0.002 (range: 0.00 - 005);
the rate of MI was 0.04 (range: 0.01 - 0.12); and
the rate of technical failure requiring revascularisation was 0.02 (range: 0.01 - 0.06) with PTCA and 0.02 (range: 0.01 - 0.06) with CABG.
Long-term outcomes (longer than 1 month):
the relative risk (RR) of mortality due to coronary artery disease was 2.14 (range: 1.5 - 3.0) in the first year and 1 (range: 1.0 - 3.0) per year in the follow-up period;
the RR of mortality due to MI was 5 (range: 4 - 6);
the RR of mortality due to stroke was 5 (range: 2 - 6) in the first year and 2 (range: 2 - 6) per year in the follow-up;
the RR of mortality due to congestive heart failure was 8 (range: 6 - 10);
the RR of mortality due to arrhythmia was 1 (range: 1 - 3);
the rate of MI was 0.02 (range: 0.01 - 0.09);
the rate of arrhythmia, given MI, was 0.041 (range: 0.03 - 0.30);
the rate of congestive heart failure, given MI, was 0.041 (range: 0.03 - 0.30);
the rate of repeated and additional revascularisation with PTCA was 0.11 (range: 0.07 - 0.20) in the first year and 0.024 (range: 0.01 - 0.03) per year in the follow-up;
the rate of repeated and additional CABG was 0.03 (range: 0.01 - 0.06) in the first year and 0.006 (range: 0.001 - 0.03) per year in the follow-up.
The odds ratio of drug-eluting stents versus bare-metal stents revascularisation was 0.26 (range: 0.14 - 0.45).
QOL reduction coefficients were as follows:
for coronary artery disease (before treatment), 0.74 (range: 0.64 - 0.84);
for MI, 0.91 (range: 0.81 - 0.98);
for major stroke, 0.61 (range: 0.51 - 0.71);
for arrhythmia, 1.00 (range: 0.89 - 1.0); and
for congestive heart failure, 0.88 (range: 0.78 - 0.98).